I haven’t read all the comments and missed the l

I haven’t read all the comments and missed the last 10 or so minutes of the call. But my takeaway:

Almost total focus on Covid right now to expedite enrollees in Cd12. The fact they have someone on the road until they achieve the remaining 45 or so patients is encouraging and a big step forward
Forming a team of doctors to be “ the face of Leronlimab” who have actually used the drug on their patients and can speak to physicians is a huge plus. They will act like a sales team but with more credibility to the doctors who have patients in need. They can answer very specific questions in a “doctor to doctor” way that most sales people cannot do.
The fact NP said we were number 4 or 5 on a hospitals priority list until our guy showed up should underline the criticality of a sales team and how some of these mediocre drugs with very little effectiveness make their way into treating covid patients and why small Biotech firms always face a headwind when they don’t have drugs already in the market and a sales team behind it.

I am glad NP mentioned why they have so many meetings with shareholders. We had this discussion just a day or two ago on this board and he confirmed my point. When the bulk of the buyers are in an OTC stock the company has to have these meetings constantly to try to keep everyone on the boat.

The OWS conversation was also important and that the head of it was in conversations with Cytodyn.that definitely opens financing opportunity should there be a need for fresh capital to significantly turn up the crank on manufacturing .

The CSO along with new hires will also get the BLA pieces together in a more knowledgeable way to read ice the chances for errors in the filings .

So, as expected, a progress report but no announcements . So I think going forward when we have the next meeting , everyone now knows why NP has these so we won’t have speculations on announcements going forward. Those will be in press release before or after the market closes..